Comparison of the utility of multiple breath inert gas washout parameters in cystic fibrosis

Ventilation inhomogeneity, measured using multiple breath washout (MBW), reflects small airway function and has emerged as a valuable tool in cystic fibrosis (CF). Improved sensitivity to detect early lung damage has been suggested from preschool children through to adults and confirmed in high-resolution CT (HRCT) studies. Longitudinal utility is now emerging. A large number of parameters reflecting overall ventilation inhomogeneity have been proposed, but consensus is lacking about the optimal parameter to report.

The two most commonly reported are lung clearance index (LCI) and moment ratios (MR). LCI, the easier to calculate and understand conceptually, represents the number of lung turnovers (or functional residual capacities, FRC) required to reduce the end tidal inert gas concentration to 1/40th of its starting value. The calculation of MR adds more weight to the latter portion of the washout curve and, while more complicated in their derivation, offer improved robustness to variations in tidal volume (VT) and potentially improved sensitivity. Truncation of MR to facilitate comparison between subjects is recommended. In practice, however, the large VT fluctuations used by Saeid et al are beyond that seen during routine MBW tests, which encourage regular tidal breathing. The derivation of these parameters is described in more detail in the online supplement.

MBW tests from two cohorts, a CF (n=56) and a healthy control (n=32), containing preschool children through to adults were retrospectively studied. Testing, performed in triplicate with results averaged, took place at the West-Swedish CF Centre, Göteborg, Sweden using equipment previously described. In children a regular spontaneous breathing pattern was targeted, while an adult protocol was used in older subjects. Spirometry was performed according to ATS criteria and z-scores were generated from appropriate Swedish reference values. LCI and MR results from the healthy cohort generated upper limits of normality. Prism Version 4.0 (GraphPad Software, San Diego, USA) was used for statistical analyses: t-tests were used for parametric continuous variables, the Mann-Whitney test for non-parametric continuous variables and multivariate logistic regression analyses to investigate factors influencing the within-subject coefficient of variation (CV) of MBW indices from the triplicate tests. Data were pooled from previous studies with ethics approval, and some of the LCI CF data have been previously reported.

The diagrammatic characteristics of the two groups are summarised in table 1 of the online supplement. MBW indices were significantly raised in the CF cohort compared with controls: LCI 9.03 (2.51) vs 6.28 (0.58); µ1/µ0 2.01 (0.55) vs 1.45 (0.12); and µ2/µ0 6.59 (3.76–30.4) vs 3.85 (2.96–5.43), all p<0.001 (see table 2 in the online supplement). Comparable sensitivity was seen between parameters and was not affected by truncation of MR. No significant difference in CV was seen between LCI and µ1/µ0 in either cohort, but was significantly greater for µ2/µ0 in both (p<0.001). Truncation of MR improved the CV in the CF cohort (table 3 in online supplement). Variation in breathing parameters (respiratory rate, mean (CV), VT (CV), or VT/FRC) did not explain the variation in CV seen between the indices. Correlation was strong between LCI and both MR parameters in the CF cohort but negatively affected by truncation at higher LCI values (figure 1) (see also figure 1 in online supplement).

While MR truncation improved stability and did not affect sensitivity, a negative effect on the relationship with LCI was seen at higher LCI values, potentially affecting sensitivity and utility in more severe disease. Given the frequency of higher LCI values reported in established CF lung disease and its comparable sensitivity and stability to µ1/µ0, this easily derived and simple to interpret index should be the preferred longitudinal assessment outcome parameter of ventilation inhomogeneity reported in future CF studies.

Association of PHF11 polymorphisms with asthma and allergy

Two recent reports in Thorax failed to show an association between polymorphisms within PHF11 and asthma phenotypes. Against this, there is evidence for an association between PHF11 and one or more phenotypes of total immunoglobulin E (IgE), atopic eczema and asthma in six independent cohorts. Here, we argue in support of the continued investigation into the biological role of PHF11 in the unravelling of the pathogenesis of atopic disease and asthma.

In the report by McClenaghan et al, positive associations were identified but lost...
upon correction for multiple testing; this approach is arguably overconservative given that it is a replication analysis. The study was powered to detect an association with an OR of at least 1.46, an OR the authors consider a requirement for ‘a major locus modifying asthma risk’. However, results emerging from genome-wide association studies of complex diseases show that apart from the human leucocyte antigen (HLA) locus it is rare to find an association with an OR of this level.

Both studies report on asthma phenotypes in non-selected cohorts drawn from the general population. Elevated total serum IgE is a marker for atopy; the mean total IgE in the twin study of McClenaghan et al was 22 IU/ml and this contrasts with 399 IU/ml in the childhood asthma study of Hersh et al and 337 IU/ml in our study of young children, all of whom developed atopic eczema by age 3. Both our study and that of Hersh et al reported an association with PHF11.

Early childhood eczema and atopic sensitisation contribute to the risk of later atopic respiratory disease. Since the initial association with PHF11 was with atopy/total IgE, we suggest that highly selected cohorts, such as young children with severe allergic disease, are better suited to detect positive single-gene associations with PHF11. In cohorts of less severely affected individuals genetic effects might only be detected by assessing gene–gene interactions, as suggested by Blakey et al. Overall, we believe an association, albeit with a modest OR, remains likely between PHF11 and IgE production/atopy in individuals afflicted by atopic asthma and eczema. Associations with low ORs may still provide important insights into the pathogenesis of complex genetic diseases; it is this principle that continues to drive the international effort in gene discovery.

Graham Jones, Graeme Stewart
University of Sydney, Westmead Millennium Institute, Institute for Immunology and Allergy Research, Westmead, Australia

Correspondence to Graham Jones, University of Sydney, Westmead Millennium Institute, Institute for Immunology and Allergy Research, Westmead 2145, Australia; graham_jones@wmi.usyd.edu.au

Competing interests None.

Provenance and peer review Not commissioned; not externally peer reviewed.

Accepted 20 September 2009

doi:10.1136/thx.2009.124511

REFERENCES
Association of *PHF11* polymorphisms with asthma and allergy

Graham Jones and Graeme Stewart

*Thorax* 2010 65: 659-660
doi: 10.1136/thx.2009.124511

Updated information and services can be found at:
http://thorax.bmj.com/content/65/7/659.2

**References**

This article cites 5 articles, 2 of which you can access for free at:
http://thorax.bmj.com/content/65/7/659.2#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/